SEC Form 4/A · accession 0001179110-15-014821
MADRIGAL PHARMACEUTICALS, INC. · MDGL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
Keith R Gollust
Director
Period of report
Nov 10, 2015
Accepted (ET)
Nov 13, 2015 · 11:20 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001157601
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3 | Nov 10, 2015 | S | 188,322 | $0.5472 | D | 2,985,061 | I | By Wyandanch Partners, L.P. |
| Common Stock | holding | — | — | — | 401,764 | D | ||
| Common Stock | holding | — | — | — | 175,000 | I | By Keith R. Gollust IRA |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This Form 4/A is being filed to correct a typographical error. Box 4 of the original Form 4 filed November 12, 2015 should have stated that the securities were disposed of by the Reporting Person, not acquired.
- F2This transaction was executed in multiple trades at prices ranging from $0.5373 to $0.5537 per share. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of the beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.